Table 1.
Patient characteristics of 81 lymph node positive patients stratified by treatment with neoadjuvant or adjuvant chemotherapy. All values are median (IQR) or frequency (proportion).
| Neoadjuvant chemotherapy |
Adjuvant chemotherapy |
p-value | |
|---|---|---|---|
| Number of patients | 32 | 49 | |
| Age at surgery | 65 (58, 71) | 62 (56, 70) | 0.3 |
| Gender, male | 16 (50%) | 37 (76%) | 0.031 |
| Pathological stage | 0.023 | ||
| pT0 | 0 (0%) | 3 (6%) | |
| pTis | 2 (6%) | 1 (2%) | |
| pT1 | 0 (0%) | 1 (2%) | |
| pT2 | 4 (13%) | 7 (14%) | |
| pT3 | 19 (59%) | 14 (29%) | |
| pT4 | 7 (22%) | 23 (47%) | |
| Number of total LNs identified | 18 (12, 25) | 23 (12, 31) | 0.3 |
| Number of positive LNs detected | 2 (1, 5) | 3 (2, 5) | 0.2 |
| LN density | 0.16 (0.07, 0.29) | 0.14 (0.08, 0.30) | 0.8 |
| Histology | 0.8 | ||
| Urothelial carcinoma, NOS | 17 (53%) | 32 (65%) | |
| Micropapillary | 4 (13%) | 6 (12%) | |
| Squamous | 4 (13%) | 3 (6%) | |
| Glandular | 2 (6%) | 3 (6%) | |
| Other | 5 (16%) | 5 (10%) | |
| ACCI | 0.6 | ||
| 0 | 0 (0%) | 0 (0%) | |
| 1 | 1 (3%) | 3 (6%) | |
| 2 | 10 (31%) | 11 (22%) | |
| 3 | 8 (25%) | 11 (22%) | |
| 4 | 7 (22%) | 13 (27%) | |
| 5 | 3 (9%) | 5 (10%) | |
| 6 | 2 (6%) | 2 (4%) | |
| ≥7 | 1 (3%) | 4 (8%) |
ACCI, Age-adjusted Charlson Comorbidity Index; IQR, interquartile range; LN, lymph node; NOS, not otherwise specified